- Kooij Katherine W., Wit Ferdinand W. N. M., van Zoest Rosan A., Schouten Judith, Kootstra Neeltje A., van Vugt Michèle, Prins Maria, Reiss Peter, van der Valk Marc Liver fibrosis in HIV-infected individuals on long-term antiretroviral therapy: associated with immune activation, immunodeficiency and prior use of didanosine AIDS (London, England) 2016;30 (11):1771-1780 [PubMed]
- van der Valk Marc, Zaaijer Hans L., Kater Arnon P., Schinkel Janke Sofosbuvir shows antiviral activity in a patient with chronic hepatitis E virus infection Journal of hepatology 2017;66 (1):242-243 [PubMed]
- Willemse S. B., Baak L. C., Kuiken S. D., van der Sluys Veer A., Lettinga K. D., van der Meer J. T. M., Depla A. C. T. M., Tuynman H., van Nieuwkerk C. M. J., Schinkel C. J., Kwa D., Reesink H. W., van der Valk M. Sofosbuvir plus simeprevir for the treatment of HCV genotype 4 patients with advanced fibrosis or compensated cirrhosis is highly efficacious in real life Journal of viral hepatitis 2016;23 (12):950-954 [PubMed]
- Nichols Brooke E., Boucher Charles A. B., van der Valk Marc, Rijnders Bart J. A., van de Vijver David A. M. C. Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study Lancet infectious diseases 2016;16 (12):1423-1429 [PubMed]
- Schouten Judith, Wit Ferdinand W., Stolte Ineke G., Kootstra Neeltje A., van der Valk Marc, Geerlings Suzanne E., Prins Maria, Reiss Peter, Kooij K. W., van Zoest R. A., Elsenga B. C., Stolte I. G., Martens M., Moll S., Berkel J., Möller L., Visser G. R., Welling C., Zaheri S., Gras L. A. J., van Leeuwen E., Godfried M. H., Goorhuis A., van der Meer J. T. M., Nellen F. J. B., van der Poll T., Prins J. M., Wiersinga W. J., Postema P. G., Bisschop P. H. L. T., Serlie M. J. M., Dekker E., de Rooij S. E. J. A., Vogt L., Portegies P., Schmand B. A., Geurtsen G. J., van Eck-Smit B. L. F., de Jong M., Richel D. J., Verbraak F. D., Demirkaya N., Ruhé H. G., Nieuwkerk P. T., van Steenwijk R. P., Majoie C. B. L. M., Caan M. W. A., van Lunsen H. W., van den Born B. J. H., Stroes E. S. G. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study Clinical infectious diseases 2014;59 (12):1787-1797 [PubMed]
MD PhD M. van der Valk (Improving the understanding and management of co-morbidity and co-infection in people living with HIV)
Since the inception of the AGEhIV cohort study in 2009 I have together with the study PI prof. P. Reiss (Professor of Internal Medicine, in particular the complications of HIV treatment), acted as a senior clinical co-investigator of the study contributing to the design and excecution of a range of studies performed by successive PhD students on the study. (www.agehiv.nl)
I act as the principal investigator of the MC Free study which aims to eliminate hepatitis C infections in hiv-positive men who have sex with men.
In line with this implementation research project I am currently initiating together with prof. F. van der Waals (professor in GlobalHealth education) an HIV 'test-and-treat' implementation research project on Bonaire.
Prof. MD PhD P. Reiss (Complications of HIV and HIV treatment)
- AMC
- AbbVie B.V.
- Amsterdam Inst. for Global Health and Development
- The Kirby lnstitute, UNSW Australia
- UMC St. Radboud